All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The delayed PDUFA date and lack of labeling talks with the FDA presaged unhappy news for Amag Pharmaceuticals Inc. regarding its supplemental new drug application (sNDA) for intravenous Feraheme (ferumoxytol), and a complete response letter (CRL) came next.